Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Yingli Pharma (Bvi) Limited has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are being handled by 2 distinct examiners. Notably, both actions are concentrated within 1 distinct art unit, suggesting a focused technical area for these applications.
RAO, SAVITHA M is the busiest examiner for the company, managing 1 pending office action. Since there are 2 distinct examiners for the 2 pending office actions, the workload is split equally. The fact that both examiners are in 1 distinct art unit may allow for some consistency in the general examination approach, even though the individual examiners differ. This concentration in 1 distinct art unit simplifies the administrative oversight required for the 2 pending office actions. The company interacts with 2 distinct examiners to resolve these matters.
For a patent practitioner, the concentration in 1 distinct art unit is a positive sign for strategy consistency. While RAO, SAVITHA M and the other examiner may have different styles, they are governed by the same Biotechnology & Pharmaceuticals art unit standards. The 2 pending office actions represent a targeted prosecution effort. Successfully managing these 2 distinct examiners within the same art unit is the company's current priority.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +30.2% |
| CHICKS, ASHLI ARIANA | 1 | 60.6% | +50.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18737785 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | RAO, SAVITHA M | — |
| 18249993 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME AND USE OF SAME | CHICKS, ASHLI ARIANA | — |
| Art Unit | Apps |
|---|---|
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18737785 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | RAO, SAVITHA M | — | §112 | Non-Final OA | — | Pending | Jun 07, 2024 |
| 18249993 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, METHOD FOR PREPARING SAME AND USE OF SAME | CHICKS, ASHLI ARIANA | 1626 | §112 | Non-Final OA | — | Pending | Apr 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial